Traductor

30 September 2010

Novartis to pay $422.5 million to settle criminal, civil charges related to drug marketing

Novartis announced Thursday it will pay $422.5 million to settle criminal and civil allegations that it marketed several drugs for unapproved uses. Under the settlement, Novartis will plead guilty to one misdemeanour count of misbranding its Trileptal seizure medication and pay a fine of $185 million. The drugmaker will pay a further $237.5 million to settle civil allegations related to the marketing of Trileptal and five other drugs.

Reference Articles
Novartis to pay $422.5 million to end Trileptal probes - (Bloomberg)
Novartis agrees to $422.5 mln marketing fine - (MarketWatch)
Novartis Pharmaceuticals, a US subsidiary of Novartis, reaches settlement agreement with US Attorney's Office - (Novartis)

**Published by "First Word"

No comments:

Post a Comment

CONTACTO · Aviso Legal · Política de Privacidad · Política de Cookies

Copyright © Noticia de Salud